Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Cancer02:18

Cancer

53.5K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.5K
Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Two-dimensional materials as emerging electrocatalysts for the HER, ORR, and OER: design strategies, challenges, and prospects in sustainable energy conversion.

Physical chemistry chemical physics : PCCP·2026
Same author

Identification of gut microbiota features of diarrheic calves using the full-length 16S rRNA gene amplicon sequencing and machine learning.

Animal microbiome·2026
Same author

Potential roles of colostrum microbiota in shaping calf gut microbiota and colostrum metabolites.

JDS communications·2026
Same author

Unveiling the rumen-microbiome-brain circuit: a unique dimension of gut-brain axis in ruminants.

Journal of animal science and biotechnology·2025
Same author

Rumen Microbiota-Based Machine Learning Approach for Predicting Heat Stress and Identifying Associated Microbes.

Microbial ecology·2025
Same author

Draft genome sequence of an antimicrobial-resistant <i>Acinetobacter sp</i>. strain isolated from a catfish raised in a commercial farm.

Microbiology resource announcements·2025

Related Experiment Video

Updated: Jan 18, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.6K

Cell Death, Molecular Targeted Therapies, and Metabolic Reprogramming in EGFR-Mutant Lung Cancer.

Himani Joshi1, M Saeed Sheikh1

  • 1Department of Pharmacology, State University of New York, Upstate Medical University, 750 E Adams Street, Syracuse, NY 13210, USA.

Cancers
|September 13, 2025
PubMed
Summary

Epidermal growth factor receptor (EGFR) mutations drive non-small cell lung carcinoma (NSCLC) by altering cell signals and metabolism. Understanding these changes aids in developing targeted therapies and overcoming resistance to EGFR inhibitors.

Keywords:
Bimadenosineepidermal growth factor receptorerlotinibgefitinibmetabolismosimertinibtyrosine kinase inhibitors

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.2K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.4K

Related Experiment Videos

Last Updated: Jan 18, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.6K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.2K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.4K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metabolism

Background:

  • Non-small cell lung carcinoma (NSCLC) is a leading cause of cancer mortality worldwide.
  • Genetic aberrations, particularly mutations in the epidermal growth factor receptor (EGFR), are key drivers of NSCLC.
  • Alterations in cellular metabolism are increasingly recognized as critical factors in cancer development and progression.

Purpose of the Study:

  • To review the impact of EGFR mutations on cellular proliferation, survival, and metabolic reprogramming in NSCLC.
  • To discuss the mechanisms of action and clinical use of EGFR tyrosine kinase inhibitors (TKIs).
  • To explore challenges in EGFR-TKI resistance and potential therapeutic strategies, including immunotherapy response in EGFR-mutant NSCLC.

Main Methods:

  • Literature review of studies investigating EGFR mutations in NSCLC.
  • Analysis of signaling pathways affected by mutant EGFR.
  • Examination of metabolic reprogramming associated with EGFR alterations.
  • Review of clinical data on EGFR-TKI efficacy and resistance mechanisms.

Main Results:

  • EGFR mutations significantly influence cell proliferation, survival pathways, and metabolic reprogramming in NSCLC.
  • EGFR-TKIs induce cell death by inhibiting mutant EGFR signaling, but resistance remains a clinical challenge.
  • Fourth-generation EGFR-TKIs are being developed to overcome resistance.
  • EGFR-mutant NSCLC often shows limited response to immunotherapy, with potential mechanisms involving altered tumor metabolism and signaling.

Conclusions:

  • Targeting mutant EGFR with TKIs is a cornerstone of NSCLC therapy.
  • Understanding the interplay between mutant EGFR signaling and metabolic reprogramming is crucial for developing novel, personalized treatment strategies.
  • Further research into overcoming TKI resistance and improving immunotherapy efficacy in EGFR-mutant NSCLC is warranted.